Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

New HPV-Triggered Subtype of Cervical Cancer Discovered



Much like other subtypes of cervical cancer, the new form has been associated with HPV infection, however the virus does not seem to influence the growth of this type of tumor.

Share this!

January 13, 2017 | by Sarah Hand, M.Sc.

Researchers at the University of South Carolina have identified a new subtype of cervical cancer that has a unique association with the human papillomavirus (HPV). Much like other subtypes of cervical cancer, the new form has been associated with HPV infection, however the virus does not seem to influence the growth of this type of tumor.

According to the researchers, targeting the genomic pathways unique to this subtype of cervical cancer could result in therapies that out-perform the standard treatment. The research was published in the journal, Oncotarget.

“Cervical cancer patients are currently treated as a uniform group based on chemotherapy and radiation regimens that help the largest percentage of people; however, one third of these patients are not helped by standard therapies,” said first author Carolyn Banister, of the University of South Carolina College of Pharmacy. “We have discovered the existence of a subgroup of cervical cancers with very different genetic features. These women may benefit from alternative treatments that are not usually given to cervical cancer patients.”

Using data collected from 255 cervical cancer samples as part of the National Cancer Institute and National Human Genome Research Institute’s joint project known as The Cancer Genome Atlas, the researchers studied expression of two key oncogenes. Associated with growth of cervical cancer tumors, the researchers found that the oncogenes were either over-expressed (HPV-active class) or under-expressed (HPV-inactive class) in the cervical cancer samples.

The idea of an HPV-inactive class of cancers which grow and spread without the influence of the virus, was first reported by another research group out of the University of South Carolina. While this work was done using samples of head and neck cancer, the results can be applied to other HPV-associated cancer types.

Patients with HPV-inactive tumors were also found to have other differences when compared to their HPV-active counterparts. The median age of diagnosis for HPV-inactive cervical cancer was ten years older at 54 years, compared to 45 years, and the median survival was over 4 times shorter.

“Physicians managing cervical cancer patients should test for HPV oncogene expression in these tumors and consider personalized treatment depending on HPV activity,” said Banister. “HPV-active tumors have high expression of immunoregulatory genes and therefore may respond to immune checkpoint inhibitor therapy. In contrast, HPV-inactive tumors often have mutations in the PIK3CA/PTEN/AKT pathway, indicating that AKT kinase inhibitors may be effective treatment options for these patients.”

Keywords: HPV, Cervical Cancer, Genome


Share this with your colleagues!

GSK Malaria Vaccine to be Pilot Tested in Three African Countries

April 25, 2017 - Ghana, Kenya and Malawi will become the first countries to test GlaxoSmithKline’s (GSK) malaria vaccine in 2018.

Featured In: Life Science News

AbbVie Posts Late-Stage Clinical Trial Results for Chronic Hepatitis C Drug

April 24, 2017 - Patients with a traditionally challenging to treat subtype of hepatitis C may soon have a new treatment option for the chronic infection.

Featured In: Clinical Trials News

Study: Few Cardiovascular Benefits of Aspirin Therapy for Patients with Peripheral Vascular Disease

April 24, 2017 - A new study conducted by researchers at the University of Florida has found that aspirin therapy may not provide sufficient cardiovascular benefits for patients with peripheral vascular disease.

Featured In: Clinical Trials News


What Medical Device Manufacturers Need to Know Before Developing a Biological Safety Evaluation


A Holistic Understanding of the Patient Journey Using Multiple Data Sources

Addressing the Challenges of Type II Diabetes Global Clinical Trials via Use of High Quality Laboratory Solutions

Clinical Trial Considerations in Cerebral Protection for TAVR Patients

Enabling Multi-Analyte Analysis of Lung Cancer FFPE Samples with 3D Biology™ Technology

Copyright © 2016-2017 Honeycomb Worldwide Inc.